Subject
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Taylor & Francis. In 2021 the journal stated that it had an impact factor of 3.912. Source: Wikipedia (en)
Editions published in Expert Opinion on Emerging Drugs 200
Too many entities requested (768). Only 200 are displayed.
-
Emerging drugs for immune thrombocytopenia (ITP).
-
Emerging targeted therapies for glioma
-
Promising therapies for treatment of nonalcoholic steatohepatitis
-
Target-oriented therapy: Emerging drugs for atopic dermatitis
-
Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients
-
Emerging drugs for the treatment of anxiety
-
Emerging therapy for endometriosis
-
Emerging treatment for advanced lung cancer with EGFR mutation
-
Future treatment of gonorrhea--novel emerging drugs are essential and in progress?
-
Emerging drugs for preeclampsia--the endothelium as a target
-
Emerging drugs for the treatment of tobacco dependence: 2014 update
-
Current and emerging drug treatments for binge eating disorder
-
Emerging drugs for the treatment of gastroparesis
-
Emerging drugs for chronic kidney disease
-
Emerging therapies for the prevention and treatment of oral mucositis.
-
Emerging treatments in alopecia
-
Emerging drugs for the treatment of acne
-
Is there a need for emerging drugs for the acute respiratory distress syndrome?
-
Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients
-
Emerging gliptins for type 2 diabetes
-
Emerging drugs for myelofibrosis
-
Emerging targets for the treatment of scleroderma
-
Emerging medication for the treatment of male hypogonadism
-
Recent developments on immunotherapy for brain cancer
-
Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).
-
Emerging drugs for Duchenne muscular dystrophy
-
Reinventing primaquine for endemic malaria
-
Liposomal amphotericin B as a treatment for human leishmaniasis
-
Emerging drugs for Guillain-Barré syndrome
-
Emerging treatments for noise-induced hearing loss
-
Emerging drugs for uveitis
-
New targets, new drugs for metastatic bone pain: a new philosophy.
Subject - wd:Q5421207